Peregrine Capital Management LLC Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Peregrine Capital Management LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 588,748 shares of the medical device company’s stock after selling 29,135 shares during the period. DexCom makes up 1.4% of Peregrine Capital Management LLC’s holdings, making the stock its 15th biggest position. Peregrine Capital Management LLC’s holdings in DexCom were worth $45,787,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom during the 4th quarter worth approximately $25,000. Heck Capital Advisors LLC acquired a new stake in DexCom during the fourth quarter worth about $38,000. RPg Family Wealth Advisory LLC purchased a new position in DexCom during the third quarter worth about $57,000. Covestor Ltd boosted its holdings in DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock valued at $3,628,069 over the last quarter. 0.30% of the stock is owned by insiders.

DexCom Stock Performance

Shares of DexCom stock opened at $89.07 on Tuesday. The business has a 50-day simple moving average of $82.44 and a 200-day simple moving average of $75.49. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a market cap of $34.79 billion, a PE ratio of 53.34, a P/E/G ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. On average, equities research analysts forecast that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Analyst Ratings Changes

DXCM has been the topic of a number of recent analyst reports. Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Sanford C. Bernstein boosted their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Raymond James decreased their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $99.06.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.